Expert Review of Anticancer Therapy

Article	Citations
The RACE for children act at one year: progress in pediatric development of molecularly targeted oncology drugs	80
Prognostic impact of renin-angiotensin system inhibitors in patients with ovarian cancer: a meta-analysis of real-world evidence	72
Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review	41
An evaluation of nivolumab plus gemcitabine and cisplatin in the treatment of advanced urothelial carcinoma	40
Prostate and metastasis-directed focal therapy in prostate cancer: hype or hope?	32
Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia	28
Clinical characteristics and outcomes among patients with subcutaneous panniculitis-like T-cell lymphoma	27
Prevailing challenges in personalized treatment for metastatic renal cell carcinoma: a narrative review	27
PSMA-targeted radioligand therapy in prostate cancer: current status and future prospects	26
Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma	24
Progress in the development of tissue-based biomarkers for urothelial cancer	23
Current diagnostic and therapeutic options in de novo low-volume metastatic hormone-sensitive prostate cancer	23
2021 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma	22
Current status and novel insights into the role of metastasectomy in the era of immunotherapy	21
Efficacy and toxicity of drugs targeting KRAS G12C mutation in non-small cell lung cancer: a meta-analysis	21
Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2- breast cancer	20
Progress in histology specific treatments in soft tissue sarcoma	20
The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan	20
Current management of familial adenomatous polyposis	19
Avapritinib in unresectable or metastatic gastrointestinal stromal tumor with PDGFRA exon 18 mutation: safety and efficacy	19
Primary effusion lymphoma: therapeutic strategies targeting viral and cellular mechanisms	19
CDK4/6 inhibition in early and advanced hormone receptor-positive, HER2-negative breast cancer	18
Pembrolizumab plus lenvatinib for radically unresectable or metastatic renal cell carcinoma in the Japanese population	17
Supportive care in pediatric acute myeloid leukemia:Expert-based recommendations of the NOPHO-DB-SHIP consortium	16
Prostate cancer prediction through a hybrid deep learning method applied to histopathological image	15

An evaluation of selinexor as a maintenance therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma	14
Early detection of hepatocellular carcinoma: roadmap for improvement	14
Safety and efficacy of immune checkpoint inhibitors in patients with cancer and hepatitis B: multicentre experience in a low-middle-income country	14
NRF2/KEAP1 signaling inhibitors in gynecologic cancers	14
Management of breast cancer diagnosed during pregnancy: global perspectives	13
Outcomes after the watch-and-wait strategy and local excision treatment for rectal cancer: a meta-analysis	13
Current status of robotic surgery for hepato-pancreato-biliary malignancies	13
Relacorilant in recurrent ovarian cancer: clinical evidence and future perspectives	13
A systematic review to summarize treatment patterns, guidelines, and characteristics of patients with renal cell carcinoma in the Asia-Pacific region	13
Trastuzumab deruxtecan and other HER2-targeting agents for the treatment of HER2-positive gastric cancer	13
Deciding individual treatment for primary retroperitoneal sarcoma	13
Diagnostic significance of miRNAs as potential biomarkers for human renal cell carcinoma: a systematic review and meta-analysis	13
The trend toward more target therapy in pancreatic ductal adenocarcinoma	12
What are the key considerations for deciding on the use of CAR T-cell therapy for patients with follicular lymphoma?	12
Targeting GPRC5D in multiple myeloma	12
Anticancer properties of histone deacetylase inhibitors – what is their potential?	11
Novel breakthroughs in advanced prostate cancer management	11
Evaluating the efficacy and safety of trebananib in treating ovarian cancer and non-ovarian cancer patients: a meta-analysis and systematic review	11
The long and winding road of faecal microbiota transplants to targeted intervention for improvement of immune checkpoint inhibition therapy	11
Prevalence and molecular correlates of acquired EGFR resistance mutations in non-small cell lung cancer (NSCLC)	11
Neo-adjuvant therapies for ER positive/HER2 negative breast cancers: from chemotherapy to hormonal therapy, CDK inhibitors, and beyond	11
Differentiated thyroid cancer and positron emission computed tomography: when, how and why?	11
NECTIN-4 targeted theranostics for urothelial cancer: getting ready for primetime?	11
Efficacy of third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in advanced NSCLC with different T790M statuses tested via digital droplet polymerase chain reaction ddPCR and	11
The effect of dose reduction of CDK4/6 inhibitors on survival in postmenopausal HR+ HER2-negative metastatic breast cancer	10
Nivolumab plus ipilimumab in malignant pleural mesothelioma	10
Evolution of immunotherapy in the treatment of non-muscle-invasive bladder cancer	10
Efficacy and safety of anti-angiogenesis agents combined with chemoradiotherapy in the treatment of locally advanced cervical cancer: a meta-analysis of randomized controlled trials	10
Pembrolizumab in the first-line treatment of advanced head and neck cancer	10
Adjuvant therapy in non-small cell lung cancer: is targeted therapy joining the standard of care?	10
PROTACs in action: a novel strategy for pancreatic cancer	10
Benign and malignant cardiac masses: long-term outcomes after surgical resection	9
First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR -mutated NSCLC: a meta-analysis of randomized phase III trials	9
What’s to come in PSMA therapies and diagnostics: A summary of clinical trials involving PSMA radioligand-based therapeutic and/or diagnostic approaches with active recruitment	9
Image-guided radiotherapy (IGRT) in Lombardy, Italy: a survey by the Lombardy section of the Italian Association of Radiotherapy and Clinical Oncology (AIRO-Lombardy)	9
Immune checkpoint inhibitors: maximizing benefit whilst minimizing toxicity	9
Emerging treatment options for prostate cancer	9
Interventions to reduce the risk of side-effects of cancer treatments in childhood	9
Research progress in strategies to improve the efficacy and safety of doxorubicin for cancer chemotherapy	9
Drug–drug interaction potential among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with novel androgen receptor inhibitors	9
JARID2 activation by NFYA promotes stemness of triple-negative breast cancer cells through the PI3K/AKT pathway	9
Understanding the causes of recurrent HCC after liver resection and radiofrequency ablation	9
A neurocentric model of survivorship: rethinking success when the mind and nerves don’t recover	9
Efficacy, safety and toxicity management of adjuvant abemaciclib in early stage HR+/HER2- high-risk breast cancer	9
Radiation-induced nasopharyngeal necrosis combined with local recurrence in nasopharyngeal carcinoma: diagnosis and treatment strategies	8
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21)	8
Effect of flexible sigmoidoscopy-based screening on colorectal cancer incidence and mortality: an updated systematic review and meta-analysis of randomized controlled trials	8
LAG-3 is a promising inhibitory immune checkpoint for antitumor immunotherapy	8
Ribociclib efficacy in special populations and analysis of patient-reported outcomes in the MONALEESA trials	8
Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty	8

Oligometastases in head and neck squamous cell carcinoma patients	8
Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers	8
Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer?	8
Pembrolizumab for the adjuvant treatment of IIB or IIC melanoma	8
Girentuximab imaging in renal cancer: diamond in the rough or just ZIRCON?	8
Molecular-driven treatment for biliary tract cancer: the promising turning point	8
Clinicopathological and prognostic significance of TIMP1 expression in gastric cancer: a systematic review and meta-analysis	8
The evolution of cyclin dependent kinase inhibitors in the treatment of cancer	8
Cemiplimab for locally advanced and metastatic basal cell carcinoma	8
Ablative margins in percutaneous thermal ablation of hepatic tumors: a systematic review	7
Utilizing risk factors to guide treatment decisions in chronic lymphocytic leukemia	7
Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant?	7
The association between HALP score and survival in patients treated with immune checkpoint inhibitors	7
Contemporary understanding of myeloid-derived suppressor cells in the acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) tumor microenvironment	7
Medullary thyroid carcinoma: a narrative historical review	7
Circadian rhythm-based cancer therapy in randomised clinical trials	7
Is 2045 the best we can do? Mitigating the HPV-related oropharyngeal cancer epidemic	7
Is the use of cetuximab in the first-line treatment of recurrent/metastatic head and neck cancer still important?	7
Hepatic artery infusion chemotherapy combined with the FOLFOX regimen for the treatment of hepatocellular carcinoma: recent advances and literature review	7
Immune checkpoint inhibition in early-stage triple-negative breast cancer	7
Novel therapeutic strategies in pancreatic cancer: moving beyond cytotoxic chemotherapy	7
Contemporary management of advanced gastric and gastroesophageal adenocarcinomas	7
The current treatment approach to adolescents and young adults with acute lymphoblastic leukemia (AYA-ALL): challenges and considerations	7
From supportive care to adjunctive treatment: the evolution in time of physical exercise and nutrition in lung cancer	7
Shedding light on the side effects of immunotherapies used for leukemia: an updated review of the literature	7
Venetoclax and beyond: New Horizons in CLL and AML therapy	7
The selection of targeted therapies for relapsed or refractory advanced renal cell carcinoma	7
Management of oligometastatic and oligoprogressive renal cell carcinoma: an updated review	7
Inhibition of neuroactive ligand–receptor interaction pathway can enhance immunotherapy response in colon cancer: an in silico study	7
Post-operative serum CEA predicts prognosis in HR-positive/HER2-negative early breast cancer	7
Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer	7
The optimal management of brain metastases from gestational trophoblastic neoplasia	6
Reevaluating the promise: is primary tumor surgery really the key to survival or just a misinterpretation in de novo stage IV breast cancer?	6
Oral selective estrogen receptor degraders (SERDs) in hormone receptor-positive HER2-negative metastatic breast cancer after progression with CDK4/6 inhibitors	6
Association between event-free survival and overall survival after neoadjuvant treatment for non-small cell lung cancer: a systematic review and meta-analysis	6
Efficacy of doxorubicin and lipiodol therapy by trans-arterial chemoembolization in hepatocellular carcinoma Egyptian patients and relation to genetic polymorphisms	6
Primary site and treatment impact in unresectable metastatic colorectal cancer	6
Predictive value of PD-L1 expression in response to immune checkpoint inhibitors for gastric cancer treatment: a systematic review and meta-analysis	6
A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma	6
Drug-induced pulmonary toxicity in breast cancer patients treated with systemic therapy: a systematic literature review	6
The assessment of circulating tumor DNA associated with Wnt/β-catenin signaling pathway as a diagnostic tool for liver cancer: a systematic review and meta-analysis	6
First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC	6
Inside prostate cancer news from the 2021 ASCO Genitourinary Cancers Symposium	6
Mucosa-associated lymphoid tissue lymphoma in thymus: a SEER analysis	6
Addressing the need for more therapeutic options in neuroendocrine prostate cancer	6
Integrating PET/CT into breast cancer care: a review of recent developments	6
Chemotherapy plus single/double immunotherapy in the treatment of non-oncogene addicted advanced non-small cell lung cancer: where do we stand and where are we going?	6
Overcoming common emerging barriers to effective neoadjuvant immunotherapies	6
Is the ketogenic diet still controversial in cancer treatment?	6
Predicting neoadjuvant chemoradiotherapy response with functional imaging and liquid biomarkers in locally advanced rectal cancer	6
Multidisciplinary systemic and local therapies for metastatic renal cell carcinoma: a narrative review	6
Safety and hematological toxicities of PARP inhibitors in patients with cancer: a systematic review of randomized controlled trials and a pharmacovigilance analysis	5
Treatment of small (T1mic, T1a, and T1b) node-negative HER2+ breast cancer – a review of current evidence for and against the use of anti-HER2 treatment regimens	5
Factors influencing survival in metastatic castration-resistant prostate cancer therapy	5
Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatment	5
Clarifications and comments on “infrared radiation for cancer hyperthermia: the light to brighten up oncology”	5
Relugolix in the management of prostate cancer	5
Surgical management of intrahepatic cholangiocarcinoma	5
FLT3 -mutated AML: immune evasion through exosome-mediated mechanisms and innovative combination therapies targeting immune escape	5
The Wnt/β-catenin pathway in breast cancer therapy: a pre-clinical perspective of its targeting for clinical translation	5
Efficacy and safety of neoadjuvant therapy for triple-negative breast cancer: a Bayesian network meta-analysis	5
Immune checkpoint inhibitors for recurrent endometrial cancer	5
Therapeutic patterns and outcomes in older patients (aged≥65 years) with stage III-IVB inoperable oral cavity squamous cell carcinoma (OCSCC): an investigational study from the SEER database	5
Safety of PD-L1 inhibitors versus PD-1 inhibitors in the treatment of lung cancer: a systematic review and network meta-analysis	5
Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma	5
The investigational role of cytoreductive stereotactic ablative radiation therapy (SABR) to the primary tumor in metastatic kidney cancer	5
Prognostic value of circulating long non-coding RNAs in colorectal cancer patients: a meta-analysis	5
Development of a nomogram for predicting postoperative recurrence of cervical intraepithelial neoplasia using immunohistochemical and clinical parameters	5
How can we refine the prognostic stratification of triple-negative breast cancer?	5
Immune senescence in non-small cell lung cancer management: therapeutic relevance, biomarkers, and mitigating approaches	5
Combined endocrine and targeted therapy in luminal breast cancer	5
The multidisciplinary management of locally advanced rectal cancer	5
Desmoplastic small round cell tumor: from state of the art to future clinical prospects	5
The role of planetary health in urologic oncology	5
Analysis of the efficacy of paclitaxel combined with bevacizumab intraperitoneal instillation in common gastrointestinal malignant peritoneal effusions and screening of prognostic indicators	5
Diagnostic performance of urine and blood microRNAs for bladder cancer: a meta-analysis	5
An evaluation of vimseltinib for treatment of tenosynovial giant cell tumors	4
Recent advances in photodynamic therapy combined with chemotherapy for cervical cancer: a systematic review	4
Current and emerging treatment options for BRAFV600-mutant melanoma	4
Therapeutic options in thymomas and thymic carcinomas	4

The evolving role of multidisciplinary teams in optimizing non-muscle invasive bladder cancer care	4
Tebentafusp for the treatment of HLA-A*02:01–positive adult patients with unresectable or metastatic uveal melanoma	4
Repurposing antipsychotic drugs for cancer treatment: current evidence and future perspectives	4
Immune checkpoint inhibitors and cardiotoxicity: possible mechanisms, manifestations, diagnosis and management	4
Avelumab in locally advanced or metastatic urothelial carcinoma	4
How can we address the challenge of distant metastases in HNSCC prognosis?	4
Advanced delivery of leuprorelin acetate for the treatment of prostatic cancer	4
Allogeneic transplantation and cellular therapies in cutaneous T-cell lymphoma	4
Bevacizumab-containing treatment for relapsed or refractory Wilms tumor	4
The effect of mechanical force in genitourinary malignancies	4
Targeted therapies in advanced biliary malignancies: a clinical review	4
Advances and future directions in radiopharmaceutical delivery for cancer treatment	4
A meta-analysis of UCA1 accuracy in the detection of bladder cancer	4
The growing role of rucaparib in contemporary treatment of metastatic prostate cancer: a review of efficacy and guidance for side effect management	4
Neutrophil-to-lymphocyte ratio predicts survival of patients with rectal cancer receiving neo-adjuvant chemoradiation followed by radical resection: a meta-analysis	4
RASGEF1C affects aerobic glycolysis and facilitates lung cancer progression through the PLK1 signaling pathway	4
PSMA PET or conventional imaging in metastatic hormone-sensitive prostate cancer?	4
Clear cell sarcoma: state-of-the art and perspectives	4
Cancer immunotherapy efficacy and machine learning	4
Balancing efficacy with long-term side-effects: can we safely de-escalate therapy for germ cell tumors?	4
Immune checkpoint inhibitor resumption after discontinuation due to immune-related adverse events: a nomogram-based analysis of risk factors and outcomes	4
The role of immunotherapy plus chemotherapy versus chemotherapy alone as first-line treatment for advanced non-small cell lung cancer: an updated systematic review and meta-analysis of randomized cont	4
Current androgen receptor antagonists under investigation for resistant prostate cancer: progress and challenges	4
Treatment of basal cell carcinoma with intralesional interferon alfa-2b: an open-label clinical trial	4
Medical imaging and multimodal artificial intelligence models for streamlining and enhancing cancer care: opportunities and challenges	4
Risk factors for the development of local recurrence in extremity soft-tissue sarcoma	3
The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia/lymphoma: challenges, opportunities, and future directions	3
Lisocabtagene maraleucel for relapsed or refractory large B-cell non-Hodgkin lymphoma	3
Efficacy and safety of nivolumab plus ipilimumab versus nivolumab alone in patients with advanced melanoma: a systematic review and meta-analysis	3
Contemporary management of diffuse large B-cell lymphoma in Japan	3
Adjuvant therapy for patients with renal cell carcinoma following surgery: a focus on pembrolizumab	3
Neopterin as a potential prognostic and predictive biomarker in metastatic renal cell carcinoma treated with immune checkpoint inhibitors	3
Optimizing cystectomy outcomes in muscle-invasive bladder cancer: what’s new in 2025?	3
Immunotherapy with chemotherapy and anti-angiogenic therapy for EGFR mutated NSCLC: challenging the dogma	3
Current usage of pembrolizumab in triple negative breast cancer (TNBC)	3
Synergistic strategies: histone deacetylase inhibitors and platinum-based drugs in cancer therapy	3
Increasing the accuracy of colorectal cancer screening	3
Association between CD8+ tumor-infiltrating lymphocytes and prognosis of non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors: a systematic review and meta-analysis	3
The incidence and relative risk of major adverse cardiovascular events and hypertension in patients treated with immune checkpoint inhibitors plus tyrosine-kinase inhibitors for solid tumors: a system	3
Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis	3
Efficacy and safety analysis of vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) in the treatment of osteosarcoma: a systematic review and meta-analysis	3
Treatment of cervical cancer: overcoming challenges in access to brachytherapy	3
Molecular subtype identification and prognosis stratification by a immunogenic cell death-related gene expression signature in colorectal cancer	3
Implementation of a CAR-T cell therapy program in India	3
Re-irradiation for recurrent/progressive pediatric brain tumors: from radiobiology to clinical outcomes	3
Human oncogenic viruses: an overview of protein biomarkers in viral cancers and their potential use in clinics	3
Consideration of quality of life in the treatment decision-making for patients with advanced gastroenteropancreatic neuroendocrine tumors	3
20 years of Expert Review of Anticancer Therapy	3
Comparative analysis of the long-term outcomes of segmentectomy and lobectomy for stage IA1 lung adenocarcinoma in patients with or without previous malignancy of other organs: a population-based stud	3
Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinoma	3
Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment	3
Current androgen receptor antagonists under investigation for resistant prostate cancer	3
Integrating supportive care into the multidisciplinary management of lung cancer: we can’t wait any longer	3
Efficacy and safety of neoadjuvant combination immunotherapy in surgically resectable malignant solid tumors: a systematic review and meta-analysis	3
Melanoma neoadjuvant treatment: review and update of recent trials	3
Optimizing adjuvant and post-neoadjuvant therapy in HER2-positive early breast cancer	3
The PI3K signaling pathway; from normal lymphopoiesis to lymphoid malignancies	3
Efficacy and safety of chemotherapy regimens for first-line treatment of advanced esophageal squamous cell carcinoma in Asia: a systematic review	3
Understanding the link between aspartame and cancer	3
Prognostic and clinicopathological value of CDK12 mutation in prostate cancer: a meta-analysis	3
Implementing machine learning to predict survival outcomes in patients with resected pulmonary large cell neuroendocrine carcinoma	3
Radiation therapy for triple-negative breast cancer: from molecular insights to clinical perspectives	3
Surveillance for hepatocellular carcinoma: current status and future perspectives for improvement	3
Surgery versus radiotherapy for older patients (aged≥65 years) with stage I-II laryngeal cancer: an investigational study from the SEER database	3
The predictive value of MiR-221 in cancer chemoresistance: a systematic review and meta-analysis	3
Medullary thyroid carcinoma	3
Hot topics in renal cancer pathology: implications for clinical management	3
The new insights of surgery for locally advanced head and neck cancer	3
Positron emission computed tomography targeting urokinase plasminogen activator receptor (uPAR) in cancer: a systematic review	3
Novel therapies for metastatic prostate cancer	3
Overview and recent advances in incidental meningioma	3
PARP inhibitor resistance mechanisms and PARP inhibitor derived imaging probes	3
Prognostic value of the nodal yield in oral squamous cell carcinoma: a systematic review and meta-analysis	3
Risk factors for secondary neoplasms in retinoblastoma survivors: a systematic literature review	3
How do non-coding RNAs impact treatment regimens currently being used in AML?	3
The use of real-world evidence to support FDA post-approval study requirements for oncology drugs	2
The new life of ibrutinib therapy in CLL: enhancing personalized approaches	2
An update understanding of stemness and chemoresistance of prostate cancer	2
Breakthrough cancer pain in the radiotherapy setting: a systematic and critical review	2
Why has targeting EGFR aberrations in glioblastoma therapy had limited success?	2
The impact of nutritional status on pancreatic cancer therapy	2
An evaluation of epcoritamab as a treatment for relapsed or refractory follicular lymphoma	2
Metastatic colorectal cancer- third line therapy and beyond	2
Five years of lenvatinib in hepatocellular carcinoma: are there any predictive and/or prognostic factors?	2
Ifosfamide-induced nephrotoxicity in oncological patients	2
Pembrolizumab plus lenvatinib combination therapy for advanced endometrial carcinoma	2
Emerging agents for the treatment of advanced or metastatic NSCLC without actionable genomic alterations with progression on first-line therapy	2
The efficacy of trastuzumab-deruxtecan for the treatment of patients with advanced HER2-low breast cancer	2
Efficacy and safety of multi-kinase inhibitors in patients with radioiodine-refractory differentiated thyroid cancer: a systematic review and meta-analysis of clinical trials	2
Alternative regimen for chemotherapy–intolerant lymphoma including practical aspects in Japan	2
Pembrolizumab as monotherapy in locally advanced cutaneous squamous cell carcinoma	2
Adapting to hormone-therapy resistance for adopting the right therapeutic strategy in advanced prostate cancer	2
The efficacy of abiraterone in metastatic hormone-sensitive prostate cancer: a stratified meta-analysis based on subgroups of low or high disease volume and reconstructed individual patient data	2
Prognostic impact of lymph node spreading pattern in N2 NSCLC patients	2
Ideal dose intensity of R-CHOP in diffuse large B-cell lymphoma	2